MOESM1 of Increased sialylation of site specific O-glycoforms of hemopexin in liver disease

Additional file 1 . Supplemental methods, figures and tables. SM 1.1. Mapping of the O-glycosylation sites. SM 1.2. Beta elimination and mass spectrometric analysis of HPX O-glycans. Table S1. Basic characteristics of disease-free controls and HALT-C participants. Table S2. The impact of IFN treatment on S-HPX. Groups of fibrotic and cirrhotic participants in the HALT-C trial were separated into the IFN treated and control arms. Table S3. Model estimates for logistic regression model in discovery set. Table S4. S-HPX measurement in the discovery and validation sets of participants. Figure S1. Precursor mass spectra confirmation of complete desialylation of HPX using 2M Acetic acid. Figure S2. ETD spectra of sialidase-treated O-glycopeptides corresponding to HILIC fractions of mono- (top), bis- (middle), and triply-glycosylated (bottom) O-glycopeptide of HPX. Figure S3. Direct quantification of S-HPX at progressing stages of liver disease divided by gender (left) and race (right; CA Caucasian, AA African-American). Figure S4. Significant associations of S-HPX and other clinical variables. Figure S5. Quantification of detected N-glycopeptides at three different N-glycosylation sequons (N64, N187 and N453) of HPX.